{"name":"UMC Utrecht","slug":"umc-utrecht","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":14,"colorKey":"neuroscience","drugs":[{"name":"Shock-dependent hydrocortisone","genericName":"Shock-dependent hydrocortisone","slug":"shock-dependent-hydrocortisone","indication":"Treatment of shock","status":"phase_3"},{"name":"Aerobic exercise","genericName":"Aerobic exercise","slug":"aerobic-exercise","indication":"Other","status":"phase_1"},{"name":"Aripiprazole depot","genericName":"Aripiprazole depot","slug":"aripiprazole-depot","indication":"Other","status":"marketed"},{"name":"Calpirinsan","genericName":"Carbasalate calcium","slug":"carbasalate-calcium","indication":"Other","status":"phase_2"},{"name":"Five-days oseltamivir + baloxavir marboxil","genericName":"Five-days oseltamivir + baloxavir marboxil","slug":"five-days-oseltamivir-baloxavir-marboxil","indication":"Acute uncomplicated influenza in adults and adolescents (treatment)","status":"phase_3"},{"name":"Fixed-duration Hydrocortisone","genericName":"Fixed-duration Hydrocortisone","slug":"fixed-duration-hydrocortisone","indication":"Adrenal insufficiency or critical illness-related corticosteroid insufficiency (investigational fixed-duration regimen)","status":"phase_3"},{"name":"Fixed-duration higher dose Hydrocortisone","genericName":"Fixed-duration higher dose Hydrocortisone","slug":"fixed-duration-higher-dose-hydrocortisone","indication":"Acute critical illness or sepsis (phase 3 investigational use)","status":"phase_3"},{"name":"LTLD","genericName":"LTLD","slug":"ltld","indication":"Other","status":"phase_1"},{"name":"Progesterone Vaginal Product","genericName":"Progesterone Vaginal Product","slug":"progesterone-vaginal-product","indication":"Luteal phase support in assisted reproductive technology (ART)","status":"marketed"},{"name":"Rivastigmine Transdermal Product","genericName":"Rivastigmine Transdermal Product","slug":"rivastigmine-transdermal-product","indication":"Other","status":"marketed"},{"name":"Sevoflurane and isoflurane","genericName":"Sevoflurane and isoflurane","slug":"sevoflurane-and-isoflurane","indication":"Other","status":"marketed"},{"name":"Ten-days oseltamivir + baloxavir marboxil","genericName":"Ten-days oseltamivir + baloxavir marboxil","slug":"ten-days-oseltamivir-baloxavir-marboxil","indication":"Treatment of acute uncomplicated influenza in patients 12 years of age and older who have been symptomatic for no more than 48 hours and who are at high risk of developing influenza-related complications","status":"phase_3"},{"name":"aspirin alone","genericName":"aspirin alone","slug":"aspirin-alone","indication":"Other","status":"marketed"},{"name":"aspirin and dipyridamole","genericName":"aspirin and dipyridamole","slug":"aspirin-and-dipyridamole","indication":"Stroke prevention","status":"marketed"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":7,"colorKey":"infectious","drugs":[{"name":"ARB + DMX-200","genericName":"ARB + DMX-200","slug":"arb-dmx-200","indication":"Hypertension (presumed primary indication based on ARB class)","status":"phase_3"},{"name":"Combined aspirin and multinutrient supplement","genericName":"Combined aspirin and multinutrient supplement","slug":"combined-aspirin-and-multinutrient-supplement","indication":"Cardiovascular disease prevention (phase 3 indication under investigation)","status":"phase_3"},{"name":"Continuation of therapeutic dose anticoagulation","genericName":"Continuation of therapeutic dose anticoagulation","slug":"continuation-of-therapeutic-dose-anticoagulation","indication":"Venous thromboembolism prevention or treatment","status":"phase_3"},{"name":"Conventional low dose thromboprophylaxis","genericName":"Conventional low dose thromboprophylaxis","slug":"conventional-low-dose-thromboprophylaxis","indication":"Thromboprophylaxis in surgical patients","status":"phase_3"},{"name":"Local standard venous thromboprophylaxis","genericName":"Local standard venous thromboprophylaxis","slug":"local-standard-venous-thromboprophylaxis","indication":"Venous thromboembolism prophylaxis in hospitalized patients","status":"phase_3"},{"name":"Therapeutic dose anticoagulation","genericName":"Therapeutic dose anticoagulation","slug":"therapeutic-dose-anticoagulation","indication":"Prevention of stroke and systemic embolism in non-valvular atrial fibrillation","status":"phase_3"},{"name":"simvastatin and ezetimibe","genericName":"simvastatin and ezetimibe","slug":"simvastatin-and-ezetimibe","indication":"Hypercholesterolemia and dyslipidemia","status":"marketed"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":7,"colorKey":"respiratory","drugs":[{"name":"Delayed administration of convalescent plasma","genericName":"Delayed administration of convalescent plasma","slug":"delayed-administration-of-convalescent-plasma","indication":"COVID-19 (delayed administration in hospitalized patients)","status":"phase_3"},{"name":"Five-days oseltamivir","genericName":"Five-days oseltamivir","slug":"five-days-oseltamivir","indication":"Influenza A and B infection treatment","status":"phase_3"},{"name":"Hydroxychloroquine + lopinavir/ritonavir","genericName":"Hydroxychloroquine + lopinavir/ritonavir","slug":"hydroxychloroquine-lopinavir-ritonavir","indication":"COVID-19 (investigational, Phase 3)","status":"phase_3"},{"name":"Moxifloxacin or Levofloxacin","genericName":"Moxifloxacin or Levofloxacin","slug":"moxifloxacin-or-levofloxacin","indication":"Community-acquired pneumonia","status":"phase_3"},{"name":"Nirmatrelvir/ritonavir + remdesivir","genericName":"Nirmatrelvir/ritonavir + remdesivir","slug":"nirmatrelvir-ritonavir-remdesivir","indication":"COVID-19 (phase 3 evaluation)","status":"phase_3"},{"name":"Standard course macrolide","genericName":"Standard course macrolide","slug":"standard-course-macrolide","indication":"Community-acquired pneumonia","status":"phase_3"},{"name":"Ten-days oseltamivir","genericName":"Ten-days oseltamivir","slug":"ten-days-oseltamivir","indication":"Influenza A and B infection treatment","status":"phase_3"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"Intermediate dose thromboprophylaxis","genericName":"Intermediate dose thromboprophylaxis","slug":"intermediate-dose-thromboprophylaxis","indication":"Thromboembolism prevention in hospitalized patients at intermediate risk","status":"marketed"},{"name":"Gallium-68-tilmanocept","genericName":"Gallium-68-tilmanocept","slug":"gallium-68-tilmanocept","indication":"PET imaging of infection and inflammation (phase 3 development)","status":"phase_3"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"cardiovascular","drugs":[{"name":"Mild stimulation","genericName":"Mild stimulation","slug":"mild-stimulation","indication":"Attention deficit hyperactivity disorder (ADHD)","status":"marketed"},{"name":"All registered antiepileptic drugs","genericName":"All registered antiepileptic drugs","slug":"all-registered-antiepileptic-drugs","indication":"Epilepsy (generalized and focal seizures)","status":"marketed"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Fixed-duration dexamethasone","genericName":"Fixed-duration dexamethasone","slug":"fixed-duration-dexamethasone","indication":"Inflammatory and immune-mediated conditions (specific indication under investigation in phase 3 trial not publicly detailed)","status":"phase_3"}]},{"name":"Respiratory","slug":"respiratory","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"rare","drugs":[{"name":"Extended course macrolide","genericName":"Extended course macrolide","slug":"extended-course-macrolide","indication":"Chronic airway inflammatory diseases (likely cystic fibrosis, bronchiectasis, or diffuse panbronchiolitis)","status":"phase_3"}]}],"pipeline":[{"name":"Fixed-duration dexamethasone","genericName":"Fixed-duration dexamethasone","slug":"fixed-duration-dexamethasone","phase":"phase_3","mechanism":"Dexamethasone is a corticosteroid that suppresses immune and inflammatory responses by binding to glucocorticoid receptors and modulating gene expression.","indications":["Inflammatory and immune-mediated conditions (specific indication under investigation in phase 3 trial not publicly detailed)"],"catalyst":""},{"name":"Intermediate dose thromboprophylaxis","genericName":"Intermediate dose thromboprophylaxis","slug":"intermediate-dose-thromboprophylaxis","phase":"marketed","mechanism":"Intermediate dose thromboprophylaxis uses anticoagulants at moderate doses to prevent blood clot formation in patients at intermediate risk.","indications":["Thromboembolism prevention in hospitalized patients at intermediate risk","Perioperative thromboprophylaxis in intermediate-risk surgical patients","Thromboembolism prevention in acute medical illness","Cancer-associated thrombosis prevention"],"catalyst":""},{"name":"Mild stimulation","genericName":"Mild stimulation","slug":"mild-stimulation","phase":"marketed","mechanism":"Mild stimulation drugs work by increasing alertness and energy levels through the activation of certain neurotransmitters in the brain.","indications":["Attention deficit hyperactivity disorder (ADHD)","Narcolepsy"],"catalyst":""},{"name":"Shock-dependent hydrocortisone","genericName":"Shock-dependent hydrocortisone","slug":"shock-dependent-hydrocortisone","phase":"phase_3","mechanism":"Shock-dependent hydrocortisone is a corticosteroid that is administered in response to shock to reduce inflammation and support the body's response to stress.","indications":["Treatment of shock"],"catalyst":""},{"name":"ARB + DMX-200","genericName":"ARB + DMX-200","slug":"arb-dmx-200","phase":"phase_3","mechanism":"ARB + DMX-200 combines an angiotensin II receptor blocker with DMX-200, a drug delivery technology designed to enhance therapeutic efficacy and potentially reduce adverse effects.","indications":["Hypertension (presumed primary indication based on ARB class)","Cardiovascular protection in phase 3 development"],"catalyst":""},{"name":"Aerobic exercise","genericName":"Aerobic exercise","slug":"aerobic-exercise","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"All registered antiepileptic drugs","genericName":"All registered antiepileptic drugs","slug":"all-registered-antiepileptic-drugs","phase":"marketed","mechanism":"Antiepileptic drugs work through multiple mechanisms including sodium channel blockade, GABA enhancement, calcium channel modulation, and other pathways to reduce neuronal excitability and prevent seizures.","indications":["Epilepsy (generalized and focal seizures)","Status epilepticus","Seizure prophylaxis","Neuropathic pain (off-label for some agents)","Bipolar disorder (off-label for some agents)"],"catalyst":""},{"name":"Aripiprazole depot","genericName":"Aripiprazole depot","slug":"aripiprazole-depot","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Calpirinsan","genericName":"Carbasalate calcium","slug":"carbasalate-calcium","phase":"phase_2","mechanism":"Calpirinsan works by binding to calcium ions, which are essential for various bodily functions.","indications":[],"catalyst":""},{"name":"Combined aspirin and multinutrient supplement","genericName":"Combined aspirin and multinutrient supplement","slug":"combined-aspirin-and-multinutrient-supplement","phase":"phase_3","mechanism":"Aspirin reduces platelet aggregation and inflammation while multinutrients provide essential vitamins and minerals to support cardiovascular health and metabolic function.","indications":["Cardiovascular disease prevention (phase 3 indication under investigation)"],"catalyst":""},{"name":"Continuation of therapeutic dose anticoagulation","genericName":"Continuation of therapeutic dose anticoagulation","slug":"continuation-of-therapeutic-dose-anticoagulation","phase":"phase_3","mechanism":"Continuation of therapeutic-dose anticoagulation maintains inhibition of blood coagulation cascade to prevent thrombotic events.","indications":["Venous thromboembolism prevention or treatment","Atrial fibrillation stroke prevention","Acute coronary syndrome","Mechanical heart valve thromboprophylaxis"],"catalyst":""},{"name":"Conventional low dose thromboprophylaxis","genericName":"Conventional low dose thromboprophylaxis","slug":"conventional-low-dose-thromboprophylaxis","phase":"phase_3","mechanism":"Conventional low-dose thromboprophylaxis prevents blood clot formation by inhibiting coagulation cascade factors, typically using anticoagulants at reduced doses for prevention rather than treatment.","indications":["Thromboprophylaxis in surgical patients","Thromboprophylaxis in orthopedic surgery patients","Thromboprophylaxis in medical patients at risk for venous thromboembolism"],"catalyst":""},{"name":"Delayed administration of convalescent plasma","genericName":"Delayed administration of convalescent plasma","slug":"delayed-administration-of-convalescent-plasma","phase":"phase_3","mechanism":"Convalescent plasma transfers antibodies and immune factors from recovered patients to provide passive immunotherapy against infectious disease.","indications":["COVID-19 (delayed administration in hospitalized patients)"],"catalyst":""},{"name":"Extended course macrolide","genericName":"Extended course macrolide","slug":"extended-course-macrolide","phase":"phase_3","mechanism":"Extended course macrolide antibiotics reduce airway inflammation and modulate immune responses in chronic respiratory conditions through anti-inflammatory and immunomodulatory effects.","indications":["Chronic airway inflammatory diseases (likely cystic fibrosis, bronchiectasis, or diffuse panbronchiolitis)","Chronic obstructive pulmonary disease with inflammatory phenotype"],"catalyst":""},{"name":"Five-days oseltamivir","genericName":"Five-days oseltamivir","slug":"five-days-oseltamivir","phase":"phase_3","mechanism":"Oseltamivir is a neuraminidase inhibitor that blocks the release of influenza virus particles from infected cells, reducing viral spread.","indications":["Influenza A and B infection treatment","Influenza prophylaxis"],"catalyst":""},{"name":"Five-days oseltamivir + baloxavir marboxil","genericName":"Five-days oseltamivir + baloxavir marboxil","slug":"five-days-oseltamivir-baloxavir-marboxil","phase":"phase_3","mechanism":"This combination uses two antiviral agents with different mechanisms to inhibit influenza virus replication through dual targeting of viral neuraminidase and cap-dependent endonuclease.","indications":["Acute uncomplicated influenza in adults and adolescents (treatment)"],"catalyst":""},{"name":"Fixed-duration Hydrocortisone","genericName":"Fixed-duration Hydrocortisone","slug":"fixed-duration-hydrocortisone","phase":"phase_3","mechanism":"Fixed-duration hydrocortisone provides short-term glucocorticoid replacement or anti-inflammatory effects with a predetermined treatment duration to minimize long-term steroid exposure.","indications":["Adrenal insufficiency or critical illness-related corticosteroid insufficiency (investigational fixed-duration regimen)"],"catalyst":""},{"name":"Fixed-duration higher dose Hydrocortisone","genericName":"Fixed-duration higher dose Hydrocortisone","slug":"fixed-duration-higher-dose-hydrocortisone","phase":"phase_3","mechanism":"Hydrocortisone is a glucocorticoid that suppresses immune and inflammatory responses by binding to glucocorticoid receptors and modulating cytokine production.","indications":["Acute critical illness or sepsis (phase 3 investigational use)","Severe inflammatory conditions requiring short-term high-dose corticosteroid therapy"],"catalyst":""},{"name":"Gallium-68-tilmanocept","genericName":"Gallium-68-tilmanocept","slug":"gallium-68-tilmanocept","phase":"phase_3","mechanism":"Gallium-68-tilmanocept is a radioactive imaging agent that binds to mannose receptors on immune cells to visualize inflammation and infection sites.","indications":["PET imaging of infection and inflammation (phase 3 development)","Potential oncology imaging applications for immune cell infiltration assessment"],"catalyst":""},{"name":"Hydroxychloroquine + lopinavir/ritonavir","genericName":"Hydroxychloroquine + lopinavir/ritonavir","slug":"hydroxychloroquine-lopinavir-ritonavir","phase":"phase_3","mechanism":"This combination uses hydroxychloroquine to modulate immune response and autophagy while lopinavir/ritonavir inhibits viral protease to reduce viral replication.","indications":["COVID-19 (investigational, Phase 3)"],"catalyst":""},{"name":"LTLD","genericName":"LTLD","slug":"ltld","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Local standard venous thromboprophylaxis","genericName":"Local standard venous thromboprophylaxis","slug":"local-standard-venous-thromboprophylaxis","phase":"phase_3","mechanism":"Local standard venous thromboprophylaxis prevents blood clots in veins through established anticoagulant or mechanical methods applied according to institutional protocols.","indications":["Venous thromboembolism prophylaxis in hospitalized patients","Post-operative thromboprophylaxis"],"catalyst":""},{"name":"Moxifloxacin or Levofloxacin","genericName":"Moxifloxacin or Levofloxacin","slug":"moxifloxacin-or-levofloxacin","phase":"phase_3","mechanism":"Moxifloxacin and Levofloxacin are broad-spectrum antibiotics that inhibit DNA gyrase and topoisomerase IV, enzymes critical for bacterial DNA replication.","indications":["Community-acquired pneumonia","Skin and skin structure infections"],"catalyst":""},{"name":"Nirmatrelvir/ritonavir + remdesivir","genericName":"Nirmatrelvir/ritonavir + remdesivir","slug":"nirmatrelvir-ritonavir-remdesivir","phase":"phase_3","mechanism":"This combination uses nirmatrelvir/ritonavir to inhibit SARS-CoV-2 protease and remdesivir to inhibit viral RNA polymerase, targeting two critical steps of viral replication.","indications":["COVID-19 (phase 3 evaluation)"],"catalyst":""},{"name":"Progesterone Vaginal Product","genericName":"Progesterone Vaginal Product","slug":"progesterone-vaginal-product","phase":"marketed","mechanism":"Progesterone binds to progesterone receptors in the reproductive tract to support luteal phase function and maintain pregnancy.","indications":["Luteal phase support in assisted reproductive technology (ART)","Pregnancy maintenance in women with progesterone deficiency"],"catalyst":""},{"name":"Rivastigmine Transdermal Product","genericName":"Rivastigmine Transdermal Product","slug":"rivastigmine-transdermal-product","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Sevoflurane and isoflurane","genericName":"Sevoflurane and isoflurane","slug":"sevoflurane-and-isoflurane","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Standard course macrolide","genericName":"Standard course macrolide","slug":"standard-course-macrolide","phase":"phase_3","mechanism":"Macrolides inhibit bacterial protein synthesis by binding to the 50S ribosomal subunit.","indications":["Community-acquired pneumonia","Acute exacerbations of chronic bronchitis","Mild to moderate asthma"],"catalyst":""},{"name":"Ten-days oseltamivir","genericName":"Ten-days oseltamivir","slug":"ten-days-oseltamivir","phase":"phase_3","mechanism":"Oseltamivir is a neuraminidase inhibitor that blocks the release of influenza virus particles from infected cells, reducing viral spread.","indications":["Influenza A and B infection treatment","Influenza prophylaxis"],"catalyst":""},{"name":"Ten-days oseltamivir + baloxavir marboxil","genericName":"Ten-days oseltamivir + baloxavir marboxil","slug":"ten-days-oseltamivir-baloxavir-marboxil","phase":"phase_3","mechanism":"Oseltamivir is a neuraminidase inhibitor that blocks the release of influenza virus from infected cells, while baloxavir marboxil is a cap-dependent endonuclease inhibitor that blocks viral replication.","indications":["Treatment of acute uncomplicated influenza in patients 12 years of age and older who have been symptomatic for no more than 48 hours and who are at high risk of developing influenza-related complications"],"catalyst":""},{"name":"Therapeutic dose anticoagulation","genericName":"Therapeutic dose anticoagulation","slug":"therapeutic-dose-anticoagulation","phase":"phase_3","mechanism":"Direct Factor Xa inhibition prevents the coagulation cascade.","indications":["Prevention of stroke and systemic embolism in non-valvular atrial fibrillation","Treatment of deep vein thrombosis and pulmonary embolism"],"catalyst":""},{"name":"aspirin alone","genericName":"aspirin alone","slug":"aspirin-alone","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"aspirin and dipyridamole","genericName":"aspirin and dipyridamole","slug":"aspirin-and-dipyridamole","phase":"marketed","mechanism":"Small molecule","indications":["Stroke prevention"],"catalyst":""},{"name":"simvastatin and ezetimibe","genericName":"simvastatin and ezetimibe","slug":"simvastatin-and-ezetimibe","phase":"marketed","mechanism":"Simvastatin inhibits cholesterol synthesis while ezetimibe blocks dietary cholesterol absorption, together reducing LDL cholesterol levels.","indications":["Hypercholesterolemia and dyslipidemia","Cardiovascular disease prevention in patients requiring additional LDL-C lowering"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxQRUwyU2EzVVdpdzlPTmtSWEt1VmNSX3JPTjRraEgtT2JYU1BCUFhKb1FiVkV0OW5GS1J0cmJsNFRKS1JnRU0ySGtQVktLZnRNcUxmY1pYcVc1WVlLNXE5dFJWYWQtRl9Lak9CNnRBSi14T292UGR3a09VZlhuakhWUkZjYzZsTTdwWUZRYUM2dnJKRUhESzdjLWRwblNpZmc0Yjg3eXprd25mQko3aWNDR3AybEpsbHFLNWgwOGtyRkNDZzJqSGc?oc=5","date":"2026-01-09","type":"pipeline","source":"Uppsala universitet","summary":"Faculty of Pharmacy confers 10 new doctors – Department of Medicinal Chemistry - Uppsala universitet","headline":"Faculty of Pharmacy confers 10 new doctors – Department of Medicinal Chemistry","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi8wFBVV95cUxNZFJrTkJ5aGVOeGRteTV6Y1FGUG9ZUEhac3VFcHh0WDBLR2h3SVVjU19wdDRnV1lMT2tra2w5YXVYTk9JZHNjYVBUeFh1VUtsa2xaVWFuY2VXb1BLWHJMRDdhZHdfTGRRd1FuUEp0ZGNKNGZJX2Q5b1FzdDE2X19hc2VkbFdreG5LeXJjZ0pDdXZFekV6UTZnVWE2LUlKNVFsS1RFZDl5TGxIZUV1V2dJRUVmcmtFaVNkbVFMTUI3RnpyeXlHT191XzRjVm1oeklXVlpUa1JaRkpscnY0OG1mM1Q4VDVBRGVUWVgzU1lEZFRUWVE?oc=5","date":"2025-12-08","type":"pipeline","source":"globenewswire.com","summary":"UMC Utrecht Selects PathAI’s AISight® Dx to Accelerate Research on AI Pathology Algorithms - globenewswire.com","headline":"UMC Utrecht Selects PathAI’s AISight® Dx to Accelerate Research on AI Pathology Algorithms","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTFAweUFHUW9JR2hPTDFYV2NMWURFMURBTlJhZ3VUaXl6YjlPcWNXRmYySzYxX3JmTnBickhZWXk5X2xNTm1nLTZpLTFQUjZMeFF5RnVn?oc=5","date":"2025-12-04","type":"pipeline","source":"The Pharma Letter","summary":"Laigo Bio - The Pharma Letter","headline":"Laigo Bio","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiXEFVX3lxTE43TjFFVE1kM0NIc2xMRlYyVFYwLXFwcWxoWl9HMTB3U09QQnRGU2lhTGhweElTbldaLTh3eG1NQWhFbk16UmtrektKempseVRCMDlpcmhWRnpJeXdX?oc=5","date":"2025-11-19","type":"pipeline","source":"EurekAlert!","summary":"New antibodies developed that can inhibit inflammation in autoimmune diseases - EurekAlert!","headline":"New antibodies developed that can inhibit inflammation in autoimmune diseases - EurekAlert!","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTFBaNXJKYXdMZlQ1cEdGdFVpaTI0WEIyV3FPMk41bGZXbGpqaXplMFlmZ2Nud0NBLU03MmVfaThZTDc4OHJBYnVkQlNpOXNWcUdSMVdSbTluZEc2SGQyN05V?oc=5","date":"2025-07-03","type":"trial","source":"Nature","summary":"Intranasal monoclonal antibodies do not prevent respiratory infection in a randomized, controlled experimental infection trial - Nature","headline":"Intranasal monoclonal antibodies do not prevent respiratory infection in a randomized, controlled experimental infection","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAJBVV95cUxPZDhyWVA5RmxLR1JhbzN5Tm12UkxSYk5fZC1tdktxMG5OcGUydHNLYmJoZ2hTRlZGT3BtMlJwU3ZDUW5mV2xzUWpJVndCWHFxOFV0V1Q2cVN4N0hmNW96MTMyV0JTNzRCOFNEbkJuN1pTdnB6VHVfbWpSLTNHNG1OVDhEOUtzcDNRQWpPaDVPcmtpVlJQNTFZQlRuQW9XZDR1dnBXdGoxWGoxV2pMdGptLXNmOGx3RlZURC1uWmV5TEFjM0JXMHI5QndkVFh6WmtLTzdkSEJlM01zc1pycWNIeHR5bFJ4Qkt1SjV5TEV3TTJlM2FSaU5Rci1LY3lhSXMxemZhQmczMWN0OHZPS0VJbjd4bnF0YlJhTGVvOUFKQ2J4ZEFoclVTeFFoTFkwOWJxOUVabQ?oc=5","date":"2025-02-05","type":"pipeline","source":"PR Newswire","summary":"UMC Utrecht adopts Volta Labs Callisto Sample Prep System to process thousands of samples for Whole Genome Sequencing-based prenatal and postnatal testing - PR Newswire","headline":"UMC Utrecht adopts Volta Labs Callisto Sample Prep System to process thousands of samples for Whole Genome Sequencing-ba","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxOc1B5bHR6LVJqZnhHQmVveTZzMlFGbDBlcnB4aEJIek9HR3EzU09xUXhoMnZRZUx6QUtoTTh2SmRxZnhGa2JqWUpNNFNteERkdjJLRks3Ujc4YWNSY01BVzBlRFNxLWdCNGh2VGhJUmRsWk1uWkhwbnptV0RtdkJSZEZqbHc4Y0x4UkZJejBjZ1FQTlZRLU9WMGk4OG42bXpDUEJTaGFSOENPYUpf?oc=5","date":"2024-06-18","type":"pipeline","source":"PharmaTimes","summary":"UMC Utrecht and VectorY collaborate to identify biomarkers of ALS - PharmaTimes","headline":"UMC Utrecht and VectorY collaborate to identify biomarkers of ALS","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxPcjRPWjA3UXU2YndUSU1CeFRobkRjbHRJa3R0RDhYRzVHbkwwSXprd180R2MybFdsZ05lX0tldHpqbTFyV3B5YVE2YUhBMFQwZ1Q2RDMzZFVnTFZaSTVrV2VLU3FOX2t5clRrN290YkVBa1I3YmlXOU1RaVF5MEFqNWIxWEZRVTc3SjhuSjRIbkJnRlMzbTRrcDJwQ3RLRzNiaHoxVw?oc=5","date":"2024-01-25","type":"pipeline","source":"UMC Utrecht","summary":"New gene therapy reimbursed for children with MLD - UMC Utrecht","headline":"New gene therapy reimbursed for children with MLD","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiakFVX3lxTFBwQ0NqTHBNRFBTMkd6UllMTlREcm9xaXotQ3h2LW5hTmx0X0VzY1FabTNFZEhXRGZfMGF6UzRZQThQbDR2bTVKSlpjRzNwaHBtRnhnXzNmRUg3amxaZjk1NmdMNXRtZjF5Z1E?oc=5","date":"2023-12-10","type":"trial","source":"Neurology® Journals","summary":"Innovating Clinical Trials for Amyotrophic Lateral Sclerosis - Neurology® Journals","headline":"Innovating Clinical Trials for Amyotrophic Lateral Sclerosis - Neurology® Journals","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxPZ19GQXRJOEd2cjJVam9XUW15Z2tpQmRESkMtYkpKSXRrcFdEVlNBRkpQQXd0RlNXV2s4N2xGN1EzdThBMm9KU3ZUMjFTcmhpcTJVdGJ4UGhVaUJGQTdlYWticERYNTdETnRoM3hKYUdMMl96d0g4RnV4c0pJdlVqSlplMjlUak5pb2dKWEZBSWtJT3dfTU1XMkh5WFJlcHh4amc?oc=5","date":"2023-06-21","type":"pipeline","source":"UMC Utrecht","summary":"Annet van Royen has been appointed as professor - UMC Utrecht","headline":"Annet van Royen has been appointed as professor","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiyAFBVV95cUxNUlJkY0hGc3hIRlZEMFY2N0pjSVUzZkl0UnFVd3l6Nk5lV2FDWVJGSWtxRERZT3o5NzlBUzI3TVUyMXZ3R3FpWWN4QVQyUjdKaUpONDlINkV0Tjc2bVJBdXB6dnhUZm5lRWJpQ01GZVlhRFdIVGo4MTU1WThSOFM4RGJmTW9xd1U1Zm5aSU1lb29KLXhPMENoRVRrdGlzSm45RHZ6WmJZYWpEMzM3czNhOHF5bVU3SGRVTkFBdGRFSEdKNHlRbzhMQg?oc=5","date":"2022-12-05","type":"pipeline","source":"UMC Utrecht","summary":"Dec 6: KWF grant for research into neuropathic pain after cancer chemotherapy - UMC Utrecht","headline":"Dec 6: KWF grant for research into neuropathic pain after cancer chemotherapy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5AFBVV95cUxNbjJPSTJmX25HNzI1blZyRHFkdXB5QUFsbm5Pc1U2eDIya1hZVFpfTzQybzBnbXhhOElmS3B6NHV3N0xyOV9VbHE5YjRaOERjckFGY2tEbWFHbjRnX0tJeEhjSGp5WDY2RnR0RFlxb0hHUEpDSUhxOXFIU2lqSzc5MHdlN3Zqa19MOXE5MjdXNVZSN0pFUHFacDk4Yy1BU1J5ODJsdloxek12SHpuejhEQXJyck5IMjF1R2txVTZtbWdOYU1EdGtCY2xrcEJlYXhNWGZEenVvcFdnUjBhWmtQVnFpd1Q?oc=5","date":"2020-06-25","type":"pipeline","source":"UMC Utrecht","summary":"Jun 25: UMC Utrecht participates in nasal airway cell model development project for COVID-19 drugs - UMC Utrecht","headline":"Jun 25: UMC Utrecht participates in nasal airway cell model development project for COVID-19 drugs","sentiment":"neutral"}],"patents":[],"drugCount":34,"phaseCounts":{"phase_3":21,"marketed":10,"phase_1":2,"phase_2":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}